

Terbin®

Terbinafine HCl

Description: Terbinafine Hydrochloride is a synthetic broad spectrum antifungal compound. It is very effective for the treatment of dermatophytes nail infections and other tinea infections.

Mode of action: Terbinafine Hydrochloride (Terbin®) works by inhibition of squalene epoxidase enzyme of fungus which is essential for formation of ergosterol.

Pharmacokinetics: Less than 5% of dose is absorbed after topical application & >70% of dose is absorbed after oral administration. The protein binding is >99%. Approximately 70% of the administered dose is eliminated in the urine.

Composition: Terbin® 250 mg Tablet: Each tablet contains Terbinafine 250 mg.

Terbin® 15 gm Cream: Each gram contains Terbinafine Hydrochloride BP 10 mg.

Terbin® 30 gm Cream: Each gram contains Terbinafine Hydrochloride BP 10 mg.

Indications:

- Onychomycosis of the toenail or fingernail due to dermatophytes
- Fungal infections of the skin (Tinea corporis, Tinea cruris, Tinea pedis etc.)
- Hair and scalp infection (Tinea capitis)
- Cutaneous candidiasis & pityriasis versicolor

Dosage & administration: Tablet:

- Toenail Onychomycosis: 250 mg once daily for 12 weeks
- Fingernail Onychomycosis: 250 mg once daily for 6 weeks
- Tinea Cruris: 250 mg once daily for 2-4 weeks
- Tinea Pedis: 250 mg once daily for 2-6 weeks
- Tinea Corporis: 250 mg once daily for 4 weeks
- Hair and skin infections: 250 mg once daily for 2-6 weeks, or as directed by the registered physicians.

Cream:

- Tinea Cruris & Corporis: once or twice daily for 1-2 weeks
- Tinea Pedis: once daily for 1 week
- Cutaneous candidiasis & Pityriasis versicolor: once or twice daily for 2 weeks.

Contraindications: Terbin® is contraindicated in individuals with hypersensitivity to terbinafine or to any other ingredients of the formulation.

Side effects: Side effects are generally mild to moderate and transient. Most common side effects are headache, diarrhea, rash, nausea, stomach pain, change in taste etc.

Use in pregnancy & lactation: Tablet is not recommended during pregnancy. Terbinafine should not be used in nursing mothers.

Precautions: Terbin® is not recommended for patients with chronic or active liver disease. Before prescribing Terbin®, pre-existing liver disease should be assessed. Hepatotoxicity may occur in patients with and without pre-existing liver disease. Pretreatment serum transaminase (ALT and AST) tests are advised for all patients before taking Terbin® Tablets.

Drug interactions: Compounds that predominantly metabolized by CYP2D6 enzyme and co-administration of terbinafine should be done with careful monitoring and may require a reduction.

Over dosage: Clinical experience regarding overdose is limited. The symptoms of overdose included nausea, vomiting, abdominal pain, rash, headache etc.

Storage: Keep out of reach of children. Store in a dry place, below 25°C temperature and protected from light.

Packaging: Terbin® 250 mg Tablet: Each carton contains 10X1 tablets in blister pack.

Terbin® 15 gm Cream: Each carton contains 15 gm cream in lami tube.

Terbin® 30 gm Cream: Each carton contains 30 gm cream in lami tube.



Manufactured by
Opsonin Pharma Limited
Rupatali, Barishal, Bangladesh.
® Registered Trade Mark.

1017-01